In a development that has sent waves of hope through the oncology community, an investigational drug has demonstrated the ability to nearly double overall survival for patients with advanced pancreatic cancer, a disease notorious for its grim prognosis. The agent, daraxonrasib, is an oral RAS inhibitor that takes aim at one of the most stubborn genetic drivers in all of oncology. Early results, presented to a standing ovation at the American Society of Clinical Oncology (ASCO) annual meeting, showed that patients with previously treated metastatic pancreatic cancer lived a median of 13.2 months on the new drug, compared with 6.7 months for those receiving standard chemotherapy. The data mark the first time a therapy targeting the KRAS oncogene has shown this magnitude of benefit in pancreatic cancer, potentially reshaping the treatment landscape for the nearly 53,000 Americans who will die from the disease this year alone.
Pancreatic cancer has long stood apart as a molecular fortress. More than 90 percent of cases harbor mutations in the RAS family of genes, primarily KRAS, which encode small GTPase proteins that act as molecular switches controlling cell proliferation and survival. For decades, KRAS was considered undruggable because its smooth surface offered no obvious binding pockets for small molecules. That paradigm began to crack with the approval of KRAS G12C inhibitors for lung cancer, but pancreatic cancer—dominated by the G12D and G12V variants—remained largely out of reach. Daraxonrasib, developed by Revolution Medicines, belongs to a new generation of RAS(ON) inhibitors that trap the mutant protein in its active, GTP-bound state, preventing it from engaging downstream effectors. By locking the oncoprotein in an inactive configuration, the drug effectively silences the aberrant growth signals that fuel tumor progression.
The clinical data underpinning the excitement come from a randomized controlled trial that enrolled patients with metastatic pancreatic adenocarcinoma whose disease had progressed on at least one prior line of therapy. The primary endpoint was overall survival, and the separation between the two arms was striking. Median overall survival reached 13.2 months in the daraxonrasib group, a 97 percent improvement over the 6.7 months seen with chemotherapy. While response rates and progression-free survival are still being analyzed, the survival advantage alone is remarkable in a setting where incremental gains have been the norm. Equally important, the drug is administered as a daily oral tablet, which spares patients the burden of frequent intravenous infusions and allows for continuous target engagement.
Beyond the numbers, the human dimension of the results has been profound. Erin Pierce, a nurse practitioner in HonorHealth Research Institute’s Oncology Research Division, described the emotional response from patients gaining access to the medication. Many expressed deep gratitude, some moved to tears of joy, she said. That visceral reaction underscores the desperation that accompanies a pancreatic cancer diagnosis, where standard first-line chemotherapy combinations have historically offered a median survival that rarely stretches beyond a year. The Expanded Access Program (EAP) launched under a recent FDA ruling now allows HonorHealth, one of the first sites in the nation, to offer daraxonrasib to patients who have exhausted other options and cannot enroll in ongoing clinical trials.
Operationally, bringing the EAP to life required rapid-fire coordination across multiple teams. Dr. Erkut Borazanci, Medical Director of the Oncology Division, oversaw the orchestration of pharmacy workflows, drug ordering logistics, and patient-tracking systems. The goal was to ensure that once a patient was deemed eligible, there would be no friction between prescription and dispensation. Eligibility is determined on a case-by-case basis, per the EAP protocol, and is reserved for individuals with previously treated metastatic disease who lack satisfactory alternative therapies and cannot access other daraxonrasib trials, such as the registrational study NCT07573215.
The significance of daraxonrasib extends well beyond a single trial. By convincingly validating KRAS as a therapeutic target in pancreatic cancer, it primes the field for a wave of combination strategies. Researchers are already exploring pairings with immune checkpoint inhibitors, chemotherapy backbones, and other targeted agents that block parallel escape pathways. The biology of pancreatic tumors, with their dense fibrotic stroma and immunosuppressive microenvironment, suggests that durable responses will likely require attacking the disease from multiple angles simultaneously. Nevertheless, the demonstration that a RAS inhibitor can, on its own, deliver a meaningful survival benefit is a critical proof of principle.
Skeptics will note that the survival advantage, while impressive, still measures time in months rather than years, and that patient selection—potentially those with less aggressive biology—could influence outcomes. Moreover, on-target toxicities such as rash, gastrointestinal disturbances, or off-tumor inhibition of wild-type RAS proteins will need careful monitoring as the drug moves toward broader use. Still, the oncology community has rarely seen such a leap in the pancreatic cancer arena, where clinical trial failures have been the rule rather than the exception.
The ASCO standing ovation captured the moment’s emotional charge. For a disease that kills over 1,000 people worldwide every day, any agent that pushes the survival curve rightward by six or seven months is a beacon. Daraxonrasib is not a cure, but it is a harbinger—a signal that the molecular lock on pancreatic cancer may finally be picking. As the drug transitions from expanded access to potential regulatory review, it carries with it the weight of decades of frustrated research and the renewed belief that even the most recalcitrant oncogenes can be drugged.
Subject of Research: People
Article Title: Daraxonrasib Nearly Doubles Survival in Metastatic Pancreatic Cancer, Marking First KRAS Success
News Publication Date: July 7, 2026
Web References: http://www.honorhealthresearch.org/
References: Clinical trial NCT07573215; data presented at the American Society of Clinical Oncology (ASCO) annual meeting.
Keywords: pancreatic cancer, KRAS inhibitor, daraxonrasib, RAS oncogene, targeted therapy, metastatic adenocarcinoma, overall survival, HonorHealth Research Institute, Revolution Medicines, expanded access program
